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Cytotoxic activity of NK cells was estimated as related to IL-10 and TGF-β1 serum levels and Helicobacter pylori infection in gastric
cancer patients. Moreover, we sought to determine whether human gastric adenocarcinoma cells in vitro release IL-10, TGF-β1
or factor(s) aﬀecting NK cytotoxicity. The studies were conducted on 42 patients with gastric cancer (14 with I-II stage—group
1; 28 with III-IV stage—group 2) and on 20 healthy volunteers. The cytotoxicity was tested on NK cells isolated from peripheral
b l o o d .I L - 1 0a n dT G F - β1 levels were determined by ELISA. H. pylori was detected in cultures of gastric mucosa biopsies and in
direct preparations. In 71.4% patients of group 1 NK cytotoxicity and IL-10 serum levels remained within a normal range while
in 68% patients of group 2 a marked decrease was noted in cytotoxic function of NK cells, accompanied by increased levels of
IL-10 in serum. In turn, in most patients of either group, independently of NK cytotoxicity and stage grouping in the patients,
elevated serum levels of TGF-β1 were detected. Presence of H. pylori infection manifested no relationship with NK cytotoxicity,
IL-10, or the TGF-β1 serum levels. In cultures of tumour cells presence of IL-10 and TGF-β1 was demonstrated. Nevertheless,
supernatants of the cultures did not change cytotoxic activity of NK cells. Development of gastric carcinoma is accompanied by
markedly decreased cytotoxic function of NK cells and by elevated IL-10 and TGF-β1 serum levels. Gastric carcinoma cells may
release IL-10, the suppressive activity of which may in a secondary manner decrease NK cytotoxicity.
1.Introduction
Natural killer (NK) cells account for 3%–5% of human
peripheral blood lymphocytes, playing an important role
in host innate immunity, mediating cytotoxicity toward
tumours or pathogen-infected cells [1, 2]. In studies per-
formed till now on NK cell activity in gastric cancer patients
a decrease was demonstrated in their antitumor functions,
whichfollowedtumourprogression[3].Inturn,interleukin-
10 (IL-10) represents an immunoregulatory cytokine with
potent anti-inﬂammatory and immunosuppresive activities,
but exerting also stimulatory eﬀects on NK cells [4, 5].
Another cytokine that mediates suppression of immune
response as well as strong inhibition of epithelial-cell growth
involves the transforming growth factor-β (TGF-β), pro-
ducedinhumansin3highlyhomologousisoforms(TGF-β1,
TGF-β2, TGF-β3), with TGF-β1 being the most prevalent in
the circulating blood [6, 7].
Increased serum levels of IL-10 and TGF-β1w e r e
d e s c r i b e di na na d v a n c e dg a s t r i cc a n c e r[ 8, 9]. In parallel,
the link was demonstrated between bacterial infection with
Helicobacter pylori and gastric cancer [10, 11].
Studies in vitro show that H. pylori strongly activates
NK cells [12]. However, no data are till now available on2 Journal of Biomedicine and Biotechnology
interrelationshipofNKcellcytotoxicityandcirculatingIL-10
levels, in relation to H. pylori infection in gastric cancer
patients.
The present study was conducted to determine whether
NKcellcytotoxicityremainsrelatedtoserumIL-10andTGF-
β1l e v e l sa n dH. pylori infection in gastric cancer patients.
Furthermore, we sought to determine whether human
gastric adenocarcinoma cell line (AGS) in vitro releases IL-
10, TGF-β1, or factor(s) directly aﬀecting cytotoxicity of NK
cells originating from healthy individuals.
2.MaterialsandMethods
2.1. Patients. T h es t u d i e sw e r ec o n d u c t e do n4 2a d u l t
patients with histologically conﬁrmed diagnosis of gastric
adenocarcinoma. Using stage grouping according to WHO
classiﬁcation of gastric tumours [13], two groups of the
patientsweredistinguished.Group1included14patients(10
males and 4 females), 54 ± 6.2 years of age. In all individuals
of the group tumour stage of I-II was diagnosed. The second
group consisted of 28 patients (22 males and 6 females),
61 ± 7.2 years of age. In all patients of the group stage III-
IV of the disease was disclosed.
The control group included 20 adult healthy volunteers
(12 males and 8 females), 56 ± 8.0 years of age, that is,
individuals who matched the groups of patients in age and
sex.
The material for studies involved samples of peripheral
blood and biopsies of gastric mucosa, obtained during
gastroscopy 2 weeks before surgical treatment.
Alltheresearchprotocolswerereviewedandapprovedby
the Ethics Committee by the University of Medical Sciences
in Pozna´ n, Poland.
2.2. H. Pylori Detection. Biopsies of gastric mucosa were
plated on Columbia agar (bioMerieux) with 7% sheep blood
with antibiotic supplement (Helicobacter pylori Selective
Supplement Dent, Oxoid). The incubation was conducted in
microaerophilic conditions (Genbox microaer, bioMerieux)
at 37
◦C for 4 to 10 days. The isolated Helicobacter pylori
strains were identiﬁed on the basis of Gram staining as well
as by production of urease, catalase, and oxidase.
Moreover, the presence of H. pylori was identiﬁed in the
tissue sections stained with Giemsa.
2.3. Isolation of NK Cells. Peripheral blood mononuclear
cells (PBMCs) were isolated from heparinized blood by
centrifugation in the Ficoll/Isopaque density gradient (spe-
ciﬁc density 1.078g/cm3, Pharmacia) for 20 minutes at
400g. The interface cells were washed twice in PBS, scored
and suspended in PBS, and enriched with 2% foetal calf
serum (FCS; Gibco), at 107 PBMC/mL. NK cells were
isolated by the biomagnetic technique via negative selection
using EasySep Human NK cell Enrichment Kit (StemCell
Technologies). The isolated cells were washed twice and
suspended at 106 cells/mL in RPMI 1640 enriched with
10% FCS, 2mM L-glutamine (Sigma), and antibiotics. The
obtained cell preparation contained 80%–85% NK cells
(CD3− CD16+/CD56+), as demonstrated by ﬂow cytome-
try, using CD3-FITC/CD16+CD56-PE (Beckman Coulter).
Cell viability was tested using 0.5% trypan blue (following
every isolation the percentage of dead cells did not exceed
5%).
2.4. AGS Cell Line. Human gastric adenocarcinoma cell
line (AGS) termed ATCC number: CRL-1739 was obtained
from LGC Promochem. AGS cells were cultured in T-25
tissue-culture ﬂasks (Nunc) in RPMI 1640, enriched with
10% FCS, 2mM L-glutamine (Sigma), and antibiotics at
the temperature of 37
◦C, in 5% CO2 atmosphere. Before
using AGS cells as targets in cytotoxicity assay, the cells were
detached from bottom of the ﬂasks and washed twice. Cell
viability was tested using 0.5% trypan blue (the percentage
of dead cells did not exceed 5%).
2.5. Cytotoxicity Assay. NK cell cytotoxicity was determined
with the Non-Radioactive Cytotoxicity Assay (CytoTox 96
Assay, Promega) using AGS cells as targets. Every examina-
tion involved 4 independent experiments. In every exper-
iment, each well of 96-well microtitre plates (Nunc) was
charged with one of the following cell cultures: 2 × 103 AGS
(spontaneous release), 2 ×103 AGS (total lysis), 104 NK cells
(spontaneous release), and 2 × 103 AGS with 104 eﬀector
NK cells (experimental release). In preliminary experiments
the eﬀector to target cells ratio 5:1 (E/T) was found to
be suﬃcient to obtain maximum cytotoxicity of NK cells
isolated from healthy volunteers. The plates were centrifuged
at 50g for 5 minutes and incubated at 37oCi n5 %C O 2
for 4 hours. Subsequently, after centrifugation of the plates
at 500g for 5 minutes, 50 microliters of the supernatants
were transferred from every well to a fresh 96-well plate and
incubated with the CytoTox 96 Kit components, according
to the manufacturer’s protocol. The results were read using
ELISA Reader 250 (bioMerieux) at λ = 490nm. Speciﬁc lysis
wassubsequentlycalculatedfromreadoutsofabsorbance(A)
in the following manner:
% cytotoxicity = 100% × [A exp − As p o n t a n e o u s
(AGS + NK) release]/(A total lysis − As p o n t a n e o u sA G S
release).
The spontaneous release involved lactate dehydrogenase
(LDH) released from target cells or from eﬀector cells
incubated alone with the complete medium.
2.6. Studies on AGS Culture Supernatants. AGS cell line cul-
tureswereinitiatedat106 cellspermLandtheirsupernatants
were harvested after 24, 48, and 72 hours. At each time
point the cell proliferation was estimated. In the obtained
supernatants IL-10 levels were estimated. In parallel, the NK
cells isolated from blood of healthy volunteers were cultured
for 18 hours in RPMI 1640, enriched with 10% FCS, 2mM
L-glutamine (Sigma), and antibiotics at the temperature
of 37
◦C, in the atmosphere of 5% CO2 in presence or
absence of 10% of 48-hour supernatants of AGS cultures.
Then, the cells were washed twice and used for cytotoxicity
assay.Journal of Biomedicine and Biotechnology 3
Table 1: NK cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-β1 )s e r u ml e v e l si nh e a l t h yv o l u n t e e r s .
No. of healthy volunteers NK cell cytotoxicity (%) IL-10 (pg/mL) TGF-β1 (ng/mL)
mean ±SD (range in parentheses)
20 52.6 ±7.38 (44.0–68.0) 1.55 ±1.1 (1.0–3.0) 18 ±3.34 (13.5–24.0)
Table 2: NK cells cytotoxicity in patients with H. pylori-positive and H. pylori-negative gastric carcinomas.




15 7 (46.7%) 8 (53.3%) 1.0000
H. pylori-negative gastric
carcinomas
27 12 (44.4%) 15 (55.6%)
2.7. IL-10 Assay. IL-10 was estimated in serum using the
immunoenzymatic technique (ELISA), employing the high
sensitivity kits of Quantikine HS Human IL-10 Immunoas-
say (R&D Systems), detecting on the average the IL-10
concentration of 0.5pg/mL. The absorbance was read at
λ = 490nm using the Reader 250 (bioMerieux). Every result
represented a mean of three readouts from the established
standard curve.
2.8. TGF-β1 Assay. Total (active plus latent) TGF-β1w a s
estimated in serum using the immunoenzymatic technique
(ELISA), employing Quantikine TGF-β1 Immunoassay kits
(R&D Systems), detecting on the average the TGF-β1
concentration of 7.0pg/mL. The absorbance was read at
λ = 450nm using the Reader 250 (bioMerieux). Every result
represented a mean of three readouts from the established
standard curve.
2.9. Statistical Analysis. A correlation analysis between NK
cell cytotoxicity and IL-10 or total TGF-β1 serum levels was
tested by computing Spearman’s rank correlation coeﬃcient
(r). The Mann-Whitney test was performed for analysis of
thedatarelatedtoeﬀectsofstudiedAGSculturesupernatants
on NK cell cytotoxicity. Diﬀerences in distributions of
H. pylori results in studied patients were compared with




levels of immunosuppressive cytokines (IL-10, TGF-β1) in
healthy volunteers are presented in Table 1 and Figures 1 and
2.T h em e a nv a l u eo fN Kc e l lc y t o t o x i c i t yw a s5 2 .6 ± 7.38%,
while IL-10 serum level amounted, on the average, to 1.55 ±
1.1pg/mL. In turn, total TGF-β1 serum level amounted,
on the average, to 18.0 ± 3.34ng/mL. In further analysis,
the lower cutoﬀ value of the normal NK cell cytotoxicity
was deﬁned as 37.8% (i.e., at two SDs below mean normal
value), the higher cutoﬀ value of IL-10 serum level was set at























































Figure 1: NK cells cytotoxic activity (•) and serum IL-10 levels
(◦) in patients with gastric cancer and healthy volunteers. Gastric
cancer patients were divided into two groups: group 1 with stages
I-II and group 2 with stages III-IV.
thehighercutoﬀvalueofTGF-β1serumlevelwasacceptedto
be 24.68ng/mL (i.e., at two SDs above mean normal value).
Results obtained in studies on NK cell cytotoxicity, IL-
10 serum levels, and H. pylori infection in patients are
presented in Figure 1 and Tables 2, 3,a n d4.I ng r o u p1
with stage I-II gastric carcinoma, in 10 (71.4%) patients,
NK cell cytotoxicity and IL-10 serum levels remained within
normal range. In parallel, in 4 of the patients presence
of H. pylori infection was disclosed. On the other hand,
in 4 (28.6%) remaining patients a decrease was noted in
NK cell cytotoxicity accompanied by an increase in IL-10
serum levels. In one of them presence of H. pylori infection
was detected. In turn, in group 2 with stage III-IV gastric
carcinoma, in 19 (68%) patients, a reduction was noted in
NK cell cytotoxicity, accompanied by an increase in IL-10
serum levels (except of 2 cases with the IL-10 level remaining
within the normal range). In 7 of the patients presence of
H. pylori infection was detected. On the other hand, in 9
(32.1%) remaining patients NK cell cytotoxicity and IL-10
serum levels did not diﬀer from those obtained in healthy
volunteers.InthreeofthemH.pyloriinfectionwasdisclosed.
Analysis of NK cell cytotoxicity and IL-10 serum levels
demonstrated a signiﬁcant negative correlation between the4 Journal of Biomedicine and Biotechnology
Table 3: IL-10 serum levels in patients with H. pylori-positive and H. pylori-negative gastric carcinomas.




15 7 (46.7%) 8 (53.3%) 1.0000
H. pylori-negative gastric
carcinomas
27 14 (51.9%) 13 (48.1%)
Table 4: Number and proportion (%) of studied cases with elevated serum levels of immunosuppressive cytokines (IL-10, TGF-β1), as
related to stage of gastric cancer.
Gastric cancer staging No. of patients No. (%) of patients with elevated level of immunosuppressive cytokine
IL-10 only TGF-β1 only IL10 + TGF-β1
Stage I-II 14 2 (14.3%) 7 (50%) 2 (14.3%)























































Figure 2: NK cells cytotoxic activity (•) and serum TGF-β1l e v e l s
() in patients with gastric cancer and healthy volunteers. Gastric
cancer patients were divided into two groups: group 1 with stages
I-II and group 2 with stages III-IV.
variables both in group 1 (r =− 0.7398; P = .0025) and in
group 2 of the patients (r =− 0.7675; P<. 0001).
Results obtained in studies on NK cell cytotoxicity, TGF-
β1 serum levels, and H. pylori infection in studied patients
are presented in Figure 2 and Tables 4 and 5.I ng r o u p1
with stage I-II gastric carcinoma, in 9 (64.3%) patients, an
elevated level of serum TGF-β1w a sd e t e c t e db u ti no n l yt w o
of them this was accompanied by elevation in serum levels
of IL-10. In 3 of the patients presence of H. pylori infection
was detected. In turn, in group 2 with stage III-IV gastric
carcinoma, in 22 (78,6%) patients, elevated serum levels of
TGF-β1 were detected, and in 11 of them this was associated
with elevated serum levels of IL-10. In 8 of the patients
presence of H. pylori infection was detected.
Analysis of NK cell cytotoxicity and TGF-β1 serum levels
failed to demonstrate a signiﬁcant correlation between the
variables both in group 1 (r =− 0.1488; P = .6116) and in
group 2 of the patients (r = 0.3488; P = .0689).
In analysis of H. pylori infection sequels in gastric cancer

















∗P<. 05 in relation to 24h supernatant
Figure 3: Quantitation of spontaneous release of immunosuppres-
sive cytokines (IL-10, TGF-β1) by human gastric adenocarcinoma
cell line (AGS).
cell cytotoxicity, IL-10, or TGF-β1 serum levels (Tables 2, 3,
and 5).
In studies on spontaneous release of IL-10 and TGF-
β1 by gastric adenocarcinoma (AGS) cell line, presence of
the cytokine was detected in supernatants of the tumour
cell cultures harvested after 24, 48, and 72 hours (Figure 3).
Mean values of IL-10 levels in the above mentioned time
points amounted to, respectively, 1.12 ± 0.27pg/mL, 2.8 ±
0.5pg/mL, and 3.13 ± 0.32pg/mL, and the cytokine levels
noted after 48 and 72 hours were signiﬁcantly higher than
the level observed after 24 hours culture. Mean values of
TGF-β1levelsintheabovementionedtimepointsamounted
to, respectively, 12.65 ± 0.92ng/mL, 19.0 ± 1.9ng/mL,and
21.6±2.19ng/mL, and the cytokine levels noted after 48 and
72 hours were signiﬁcantly higher than the level observed
after 24-hour culture.Journal of Biomedicine and Biotechnology 5
Table 5: TGF-β1 serum levels in patients with H. pylori-positive and H. pylori-negative gastric carcinomas.




15 4 (26.7%) 11 (73.3%) 1.0000
H. pylori-negative gastric
carcinomas
27 6 (22.2%) 21 (77.8%)
Table 6: Inﬂuence of 48 hours AGS culture supernatant on NK cells activity in healthy persons.
No. of healthy
volunteers
Tested supernatant NK activity (%) mean ±SD
(range in parentheses)
P-value for diﬀerence
16 48h AGS supernatant 43.81 ±4.65 (38.0–55.0) .087
16 PBS (control) 50.56 ±7.19 (40.0–61.0)
Results of studies on the eﬀect of 48 hours supernatants
from AGS cell line cultures on cytotoxicity of healthy
volunteer’ NK cells are presented in Table 6.T h em e a n
cytotoxicity of NK cells amounted to 43.8 ± 4.65% and
manifestednosigniﬁcantdiﬀerencesfromthecontrolvalues.
4. Discussion
In the conducted studies, NK cell cytotoxicity and immuno-
suppressive cytokines (IL-10, TGF-β1) serum levels have
shown variability related to the stage of gastric carcinoma.
In most of the patients with stages I-II gastric cancer NK
cellcytotoxicityandIL-10serumlevelshaveremainedwithin
normal values, in contrast to signiﬁcantly elevated serum
levels of TGF-β1. On the other hand, in most patients with
stages III-IV of the cancer NK cell cytotoxicity has been
signiﬁcantly lowered while serum IL-10 and TGF-β1l e v e l s
have shown a signiﬁcant increase, as compared to the control
values. Therefore the presented studies on spontaneous cyto-
toxicity in patients with gastric cancer have been performed
for the ﬁrst time on NK (CD3− CD56+/CD16+) cells freshly
isolated from peripheral blood. The obtained data may, in
part, conﬁrm and verify the earlier data on a decreased NK
activity of peripheral blood lymphocytes in gastric cancer
patients with tumour progression [3, 14].
Inturn,theelevatedlevelofcirculatingIL-10inadvanced
gastric cancer was described already earlier [8, 15]b u t
results of our studies, conducted in relation to NK cell
cytotoxicity, allow to extend signiﬁcance of the cytokine in
the pathomechanism of tumour progression. The dual role
of IL-10 was already well recognized [5]. On one hand, the
cytokine exerts a direct suppressive eﬀect on functions of
monocytes/macrophages and on Th1 cell activity, strongly
inhibiting production of macrophage inﬂammatory pro-
teins, such as MIP-2α,I L - 1 β, IL-6, IL-8, IL-12, IL18, TNF-
α, and GM-CSF, and secretion of IFN-γ and IL-2 in T cells
[4]. On the other hand, IL-10 has stimulatory eﬀects on NK
c e l l sa sw e l la sc y t o t o x i cTl y m p h o c y t e s( C T L s )[ 16, 17].
Moreover, the cytokine induces a population of regulatory
cells (TReg)w h i c hp r o d u c eh i g hl e v e l so fI L - 1 0a n dT G F - β
andcansuppresstheantigen-speciﬁcimmuneresponse[18].
Our studies, however, have demonstrated a negative correla-
tion between NK cell cytotoxicity and IL-10 serum levels in
patients with gastric cancer. Therefore, the elevated levels of
IL-10 in advanced gastric cancer may inhibit production of
IFN-γ, IL-2, IL-12, and IL-18, with the resulting restricted
cytotoxic function of NK cells. The conclusion is backed
up by results of Wen et al. [19], demonstrating a decreased
activity of IFN-γ and IL-2 especially in the advanced stages
of gastric cancer. In addition, IL-2 is known to be signiﬁcant
f o rN Kc e l ld e v e l o p m e n ta n dp e r i p h e r a ls u r v i v a l[ 20]. The
cytokine also acts synergistically with both IFN-γ and IL-
12, augmenting NK cell cytotoxicity [21]. In contrast to
our results, the recently presented studies of Thong-Ngam
et al. [22] demonstrated augmented IL-18 serum levels in
gastric cancer. The cytokine, in combination with IL-10,
can enhance NK cell cytotoxicity [16]. However, in the
above quoted study the mean values of IL-18 serum level
with standard deviation were given for an only generally
deﬁned cancer patient group. Therefore, it is diﬃcult to
relate the data to the results presented here, as related to
pathological status of gastric cancer patients. As detected
by us in some patients normal NK cell cytotoxicity may
have been determined by elevated levels of circulating IL-
18 which, in combination with IL-10, upregulate NK cell
function.
In this study, H. pylori infection has involved 36% of
the patients while the obtained results related to NK cell
cytotoxicity and IL-10 serum levels have not depended
on infection with the pathogen. H. pylori infection has
already been well documented to represent an important
factor in pathogenesis of gastric cancer, inducing chronic
gastric inﬂammation [11]. In parallel, it is postulated
that promotion of gastric carcinogenesis includes also a
signiﬁcant role of H. pylori-stimulated high production of
pro-inﬂammatory cytokines, mainly of IL-1, IL-6, IL-8, and
TNF-α [23, 24]. In parallel, low levels of IL-10 multiply
the risk of gastric cancer in patients infected with H. pylori
[25]. Therefore, as demonstrated in the present study a
decreased NK cell cytotoxicity and elevation of IL-10 serum
levelsseemtorepresentasequelofneoplastictransformation
and of tumour growth. In part, the conclusion may be
backed up by observations that H. pylori disappears from6 Journal of Biomedicine and Biotechnology
the stomach with marked atrophic changes perhaps due
to lack of nutrients for this pathogen [23]. Moreover, the
in vitro experiments by Hafsi et al. [12] indicate that H.
pylori may strongly activate NK cell, but fail to exert any
direct eﬀect on NK cell cytotoxicity. In parallel, Yun et al.
[26] showed that H. pylori and IL-12 act synergistically
stimulating NK cells to high production of IFN-γ. Also,
the authors suggested that the augmented secretion of the
cytokine by NK cells induced activation of their cytotoxic
function. Our results seem to contradict the suggestion,
documenting impoverished cytotoxic activity of NK cells
in patients in the course of gastric cancer. Nevertheless,
the contradiction may be explained by data which point to
phenotypic and functional diﬀerentiation of NK cells, IFN-
γ—producing CD56bright subset and the manifesting more
cytotoxic activity CD56dim NK cells [27, 28]. In this context,
the augmented secretion of IFN-γ by NK cells does not seem
to determine the cytotoxic activity which we have estimated.
The elevated serum levels of IL-10, in turn, can hardly be
explainedexclusivelybyashifttowardsaTh2immunological
response, which accompanies development of gastric cancer,
as described by Ren et al. [29]. In our studies the elevated
serum levels of IL-10 most frequently have accompanied
an advanced gastric cancer. In such a context, the main
source of IL-10 seems to involve the tumour itself. The
suggestion may be conﬁrmed by our studies, documenting
for the ﬁrst time in vitro spontaneous release of IL-10 by
A G Sc e l ll i n e .H o w e v e r ,w eh a v ed e t e c t e dt h ee ﬀect of 48-
hour supernatants from cultures of the cells on NK cell
cytotoxicity. Documenting the absence of a direct eﬀect of
tumour-released IL-10 on cytotoxic activity of NK cells, the
observations remain in line with other results of our studies,
pointing to the potential for indirect eﬀects on the function
of NK cells.
Inturn,estimationsofTGF-β1haveshownasigniﬁcantly
elevated level of the cytokine in sera of most patients
with either stages I-II or III-IV of gastric carcinoma. The
data are consistent with results of Vagenas et al. [30]a n d
have demonstrated no relationships between high levels of
circulating TGF-β1, tumors stage, and NK cell cytotoxicity.
However, the observed elevated TGF-β1 serum levels, which
accompany gastric cancer, prove that the cytokine is involved
in pathogenesis of the disease and may provide a diagnostic
marker of tumour development. In parallel, in this study
the elevated serum levels of TGF-β1 in patients with gastric
carcinoma have been found to be not related to presence
of H. pylori infection. TGF-β1 was convincingly shown to
inhibit activity of NK cells [6]. Nevertheless, results of this
study allow to conclude that the decreased cytotoxicity of
peripheral blood NK cells has not been determined by
overproduction of TGF-β1. The conclusion is backed up
by the data pointing to presence of the cytokine in blood
circulation in an inactive, latent form, as a latency-associated
protein [31].
In turn, the elevated serum levels of TGF-β1 in the
patients, independently of the gastric carcinoma stage, can
hardly be explained by secretion of the cytokine by tumour
cells only. Thus, the obtained results may corroborate
the earlier data presented by Wakeﬁeld et al. [32] that
production of TGF-β1bythetumorcellsdoes not contribute
signiﬁcantlytothetotalTGF-β1inthebloodcirculation.The
source of an elevated serum level of TGF-β1 in the course of
gastric carcinoma has remained incompletely clariﬁed.
In conclusion, our current studies indicate that develop-
ment of gastric cancer is accompanied by a marked decrease
in cytotoxic activity of NK cells and by augmented levels of
serum IL-10 and TGF-β1. Manifestation of the disturbances
is not dependent on H. pylori infection. Moreover, data
obtained in this study indicate that gastric adenocarcinoma
cells may release IL-10 and TGF-β1. The decreased cytotoxic
function of NK cells seems to be determined mainly in a
secondary manner, by immunosuppressive activity of IL-10.
Therefore, IL-10 represents a very important “protective”
factor for the developing gastric tumour.
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